Cipla receives final approval for generic version of Biogen IDEC Inc.’s Tecfidera

▴ Cipla receives final approval for generic version of Biogen IDEC Inc.’s Tecfidera
Cipla Limited today announced that it has received final approval for its ANDA for Dimethyl Fumarate Capsules

Cipla Limited today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Dimethyl Fumarate DR Capsules 120mg, 240mg, and 120mg/240mg Starter Pak from the United States Food and Drug Administration (US FDA).

Cipla’s Dimethyl Fumarate DR Caps 120mg, 240mg, and 120mg/240mg Starter Pak is AB-rated generic therapeutic equivalent version of Biogen IDEC Inc.’s Tecfidera. It is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

According to IQVIA (IMS Health), Tecfidera had US sales of approximately $3.8 Billion for the 12-month period ending July 2020.


The product is available for shipping immediately. Cipla will be providing Co-Pay Assistance.

Tags : #LatestPharmaNewsSep25 #LatestCiplaNewsSep25 #ANDAapproval #DimethylFumarateDRCapsules #GenericversionofTecfidera #Treatmentformultiplesclerosis

About the Author


Sana Farid Khan

“The best way to become acquainted with a subject is to write about it."
A confident counselor, a speaker, and an educator, ready to utilize my communication skills effectively in the world of healthcare by putting pen to paper to reach new heights of success.
You can write to me at [email protected]

Related Stories

Loading Please wait...